Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have …
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-
related death worldwide. The treatment of HCC remains challenging and is largely …
related death worldwide. The treatment of HCC remains challenging and is largely …
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
T Powles, ZJ Assaf, N Davarpanah, R Banchereau… - Nature, 2021 - nature.com
Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Background Despite advances in early detection and therapies, cancer is still one of the
most common causes of death worldwide. Since each tumor is unique, there is a need to …
most common causes of death worldwide. Since each tumor is unique, there is a need to …
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Liquid biopsy enters the clinic—implementation issues and future challenges
M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
Circulating tumour DNA—looking beyond the blood
Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …
Clinical trial design in the era of precision medicine
E Fountzilas, AM Tsimberidou, HH Vo, R Kurzrock - Genome medicine, 2022 - Springer
Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …
unique molecular features that drive malignancies. Precision medicine has exploited next …